Studied variable | Univariate | Multivariate | ||
---|---|---|---|---|
p value | HR (95% CI) | p value | HR (95% CI) | |
Older age | 0.01 | 1.03 (1.02–1.05) | 0.01 | 1.03 (1.01–1.06) |
Sex (male) | 0.18 | 0.6 (0.4–1.18) |  |  |
Viral etiology | 0.94 | 0.9 (0.4– 2.1) |  |  |
Prior HCV treatment | ||||
 IFN | 0.57 | 1.2 (0.6–2.0) |  |  |
 DAAs | 0.28 | 0.7 (0.3–1.3) |  |  |
Serum AFP | 0.64 | 1.0 (1.0–1.0) |  |  |
Tumor focality (multiple) | 0.21 | 1.3 (0.8–1.9) |  |  |
Tumor size | 0.01 | 1.1 (1.017–1.2) | 0.007 | 1.1 (1.02–1.2) |
Pathological grade | ||||
 I | Reference |  |  |  |
 II | 0.91 | 0.9 (0.4–1.8) |  |  |
 III | 0.46 | 1.3 (0.6–2.8) |  |  |
Tumor TIL Salgado | ||||
 0–10 | Reference |  |  |  |
 20–40 | 0.03 | 0.4 (0.2–0.9) | 0.006 | 0.3 (0.2–0.7) |
Intra-tumoral fibrous stroma | ||||
 Absent | Reference |  |  |  |
 Present | 0.01 | 1.6 (1.1–2.4) | 0.002 | 1.9 (1.2–2.8) |
 Dominant | 0.01 | 2.9 (1.2–6.8) | 0.02 | 2.8 (1.2-6.6) |
Pathological stage | ||||
 1 | Reference |  |  |  |
 2 | 0.66 | 1.3 (0.3–5.7) |  |  |
 3 | 0.53 | 1.6 (0.3–7.2) |  |  |
 4 | 0.30 | 2.5 (0.4–15.5) |  |  |
Tumor stage (late) | 0.25 | 1.4 (0.7–2.5) |  |  |
Liver cirrhosis | 0.22 | 1.2 (0.8–1.9) |  |  |
LVI | 0.27 | 1.2 (0.8–2.1) |  |  |